Comment on FDA’s draft guidance on clinical trials with psychedelic drugs

The FDA is accepting public considerations for researchers investigating psychedelic drugs for the potential treatment of medical conditions such as substance use disorders. The draft guidance offers the 1st opportunity for potential research sponsors to to consider foundational aspects of designing clinical trials for psychedelic drugs.